Menu Search
Equities

ReproCell Inc

6RC:FRA

ReproCell Inc

Actions
  • Price (EUR)0.555
  • Today's Change-0.025 / -4.31%
  • Shares traded-1.00
  • 1 Year change-73.32%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

  • Revenue in JPY (TTM)2.43bn
  • Net income in JPY-31.42m
  • Incorporated2003
  • Employees92.00
  • Location
    ReproCell Inc9F, KDX Shin-Yokohama 381 Bldg.3-8-11, Shin-Yokohama, Kohoku-kuYOKOHAMA-SHI 222-0033JapanJPN
  • Phone+81 454753887
  • Fax+81 454741006
  • Websitehttps://reprocell.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.